Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

BACKGROUND: After analysis of minor RAS mutations (KRAS exon 3, 4/NRAS) in the FIRE-3 and PRIME studies, an expanded range of RAS mutations were established as a negative predictive marker for the efficacy of anti-EGFR antibody treatment. BRAF and PIK3CA mutations may be candidate biomarkers for ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Izuma, Shinozaki, Eiji, Matsushima, Tomohiro, Wakatsuki, Takeru, Ogura, Mariko, Ichimura, Takashi, Ozaka, Masato, Takahari, Daisuke, Suenaga, Mitsukuni, Chin, Keisho, Mizunuma, Nobuyuki, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223326/
https://www.ncbi.nlm.nih.gov/pubmed/28068936
http://dx.doi.org/10.1186/s12885-016-2994-6

Ejemplares similares

Ejemplares similares